Senior Research Scientist
Ph.D. in Medicinal Chemistry
Visiting Researcher, Department of Bioengineering, Graduate School of Engineering, The University of Tokyo
Research contents (Research key words)
The focus of my research has always been on chemical entities that are pharmaceutically important. My PhD research involved selective synthetic modification of the clinically important antibiotic aminoglycosides, neomycin B, paromomycin, and tobramycin, for improved efficacy in the treatment of tuberculosis. My research interest had subsequently shifted from small molecule structural modifications to the macromolecular delivery system. With a fundamental idea of overcoming inherent limitations of conventional drugs, and amplifying their therapeutic responses, supramolecular nanoassemblies or nanomedicines are getting reputes as an alternative oncologic treatment strategy. In our laboratory, we use polymeric micelle-based nanomedicines that offer a unique ability for realizing coordinated functionality, such as active targeting and spatiotemporally controlled drug action, which can efficiently transport and selectively activate the drug in the tumor microenvironment (TME). With useful biocompatible and biodegradable features, block copolymer nanomicelles are offering important clinical translation potential. As a step forward, we have developed next-generation nanomicelles that can better synchronize with intrinsic TME features, such as dysregulated pH or metabolic alteration. We have also developed tumor-targeted nanomedicine capable of treating both tumors with high and low c-Myc levels. Furthermore, the use of a clinically relevant nanomicelle, incorporating the ICD-inducing drug, has been expanded by reversing cold GBM into hot tumors to synergize the efficacy of anti-PD1 therapy.
Currently, I am acting as a PI in several projects and also coordinating international research activities at iCONM. One of my international collaborative research endeavors, "COnCorD," was one of the three bilateral projects awarded by the Spanish State Agency for Research (AEI) and the Japanese Medical Research Agency (AMED) as a result of invitation for joint project proposals from early-stage researchers in Japan and Spain in the "Nanomedicine" research area. In this project, I am acting as a PI from Japan side and Dr. Rosalia Rodríguez, an Associate Professor of Universidad Internacional de Cataluña, as a PI from Spain side.
Glioblastoma, Stimuli-Sensitive NanoMedicine, Polymer micelle, Targeted Therapy, Drug Delivery System, Organic Chemistry.
- Senior Research Scientist, Innovation Center of NanoMedicine (iCONM) (2015- current)
- Project Researcher, Department of Materials Engineering
Graduate School of Engineering, The University of Tokyo, (2013-2015)
- Postdoctoral Researcher, JSPS, Department of Materials Engineering, Graduate School of Engineering, The University of Tokyo, (2011-2012)
- Research Chemist, Research Directions Pty. Ltd. Brisbane, Australia (2007)
- Ph.D. in Synthetic Organic Chemistry, Griffith University, Brisbane, Australia (2003- 2007)
- Lecturer, Department of Chemistry, Chittagong University of Science and Technology, Bangladesh, (2001-2003).
- MSc (Research) in Applied Chemistry, University of Chittagong, Bangladesh (1999- 2000).
- Sabina Quader, Xueying Liu, Kazuko Toh, Yu-Lin Su, Amit Ranjan Maity, Anqi Tao, West Kristian D Paraiso, Yuki Mochida, Hiroaki Kinoh, Horacio Cabral, Kazunori Kataoka. Supramolecularly enabled pH-triggered drug action at tumor microenvironment potentiates nanomedicine efficacy against glioblastoma. Biomaterials, 2021, 267, 120463
- Hiroaki Kinoh, Sabina Quader, Hitoshi Shibasaki, Xueying Liu, Amit Maity, Tatsuya Yamasoba, Horacio Cabral, Kazunori Kataoka. Translational nanomedicine boosts anti-PD1 therapy to eradicate orthotopic PTEN-negative glioblastoma. ACS Nano 2020, 14, 8, 10127–10140
- Hitoshi Shibasaki, Hiroaki Kinoh, Horacio Cabral, Sabina Quader, Yuki Mochida, Xueying Liu, Kazuko Toh, Kazuki Miyano, Yu Matsumoto, Tatsuya Yamasoba, Kazunori Kataoka. Efficacy of pH-Sensitive Nanomedicines in Tumors with Different c-MYC Expression Depends on the Intratumoral Activation Profile. ACS Nano 2021, 15, 3, 5545–5559
- Sabina Quader and Kazunori Kataoka. Nanomaterial-Enabled Cancer Therapy. Molecular Therapy. 2017, 25, 1501-1513.
- Sabina Quader, Xueying Liu, Yi-Chun Chen, Peng Mi, Tsukasa Chida, Takehiko Ishii, Yutaka Miura, Nobuhiro Nishiyama, Horacio Cabral and Kazunori Kataoka. cRGD peptide-installed epirubicin-loaded polymeric micelles for effective targeted therapy against brain tumors. J. Control. Release. 2017, 258, 56-66.
- Sabina Quader, Sue E. Boyd, Ian D. Jenkins and Todd A. Houston. Multisite Modification of Neomycin B: Combined Mitsunobu and Click Chemistry Approach. J. Org. Chem. 2007, 72, 1962-1979.
Fellowship And Research Grant
- Grant-in-Aid for Scientific Research C (2021-2023)
- The Japan Society for Promotion of Science Fellowship Bilateral Joint Research Projects/Seminars Funding (2020-2021)
- Japan-Spain Joint call for Strategic International Collaborative Research Program (SICORP)- Sabina Quader and Rosalía Rodríguez-Rodríguez. (2019-2021)- amount- 21,000,000 JPY in Japan and 150,000 € in Spain.
- “Challenging Exploratory Research”- (2016-2017)- amount 3,510,000 JPY
- “Grant-in-Aid for Scientific Research”- Sabina Quader (2017-2018)-amount 2,300,000 JPY.
- The Japan Society for Promotion of Science Fellowship For Foreign Researchers (Standard), December 2010- January 2013.
Selected Invited Lectures and Symposium presentation
- Sabina Quader, West Paraiso, Xueying Liu, Hitoshi Shibasaki, Horacio Cabral, Hiroaki Kinoh, Kazunori Kataoka, Latest Advancement of Targeted Drug Therapy Using NanoMicelle. International Sessions: Evolvement of targeted drug therapy, The 79th Annual Meeting of the Japan Cancer Association, Hiroshima, October, 2020.
- Sabina Quader, Xueying Liu, Hitoshi Shibasaki, Hiroaki Kinoh, Kazunori Kataoka, “Targeting Intractable Cancers Using Tumor Extracellular pH sensitive NanoMedicine”., International Session, The 78th Annual Meeting of the Japan Cancer Association, Kyoto, September, 2019.
- Sabina Quader, “Addressing unmet medical needs- a nanomedicine based approach” National Nenotechnology Center (NANOTEC), Bangkok, Thailand. August 2019.
- Sabina Quader, "NanoMedicine to target intractable cancer.” The University of Tokyo-iCONM-NANOTEC, Joint Research Meeting on Nanomedicine, Tokyo, Japan. January 2019.
- Sabina Quader and Rosalia Rodríguez-Rodríguez, “Drug delivery targeting Brain CPT1: a novel nanomedicine-based approach to fight obesity and cancer.” Joint Japan-Spain Symposium on Medical Research, Madrid, Spain. November 2018.
- Sabina Quader, Xueying Liu, Horacio Cabral, Yu-Lin Su, Amit Ranjan Maity, Hiraoki Kinoh, Kazunori Kataoka, “Nanomedicine to Target Glioblastoma” International Session, The 77th Annual Meeting of the Japan Cancer Association, Osaka. September 2018.
- Sabina Quader and Kazunori Kataoka. “Targeting cancer using stimuli-sensitive polymeric micelle.” International Symposium on Biorelated Polymers: 255th ACS National Meeting. New Orleans, USA. March 2018.
- Sabina Quader. “Nanocarrier system for cancer therapy.” Summer School, Nanosciences, Fundamental and Applications Emphasizing in Nanomedicine. Institute of Technology Bandung, Indonesia. July 2017.
- American Chemical Society
- Japanese Cancer Association
- The Japanese Association of Molecular Target Therapy of Cancer